

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody

RRID:AB_2160222

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2605, RRID:AB_2160222

Antibody Information

URL: http://antibodyregistry.org/AB_2160222

Proper Citation: Cell Signaling Technology Cat# 2605, RRID:AB_2160222

Target Antigen: Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10078474, AB_10830737, AB_2160222.

Antibody Name: Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody

Description: This polyclonal targets Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197)

Target Organism: rat, h, gp, m, mouse, r, human

Antibody ID: AB_2160222

Vendor: Cell Signaling Technology

Catalog Number: 2605

Record Creation Time: 20250820T042031+0000

Record Last Update: 20250820T184233+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody.

No alerts have been found for Phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Park CS, et al. (2024) Fam49b dampens TCR signal strength to regulate survival of positively selected thymocytes and peripheral T cells. *eLife*, 13.

Cannon AC, et al. (2024) Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. *Oncogene*, 43(10), 729.

Nishikawa M, et al. (2024) Pathophysiological significance of the p.E31G variant in RAC1 responsible for a neurodevelopmental disorder with microcephaly. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(1), 167520.

Cannon AC, et al. (2023) Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. *bioRxiv : the preprint server for biology*.

Schaefer A, et al. (2023) RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. *Science signaling*, 16(816), eadg5289.

Seyama R, et al. (2023) A missense variant at the RAC1-PAK1 binding site of RAC1 inactivates downstream signaling in VACTERL association. *Scientific reports*, 13(1), 9789.

Gao X, et al. (2022) Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. *Molecular cell*, 82(11), 1992.

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. *Cell reports*, 39(1), 110641.

Floerchinger A, et al. (2021) Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging. *Cell reports*, 36(11), 109689.

Cooke M, et al. (2021) FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma. *Cell reports*, 37(5), 109905.

Lo LH, et al. (2020) The Protein Arginine Methyltransferase PRMT8 and Substrate G3BP1 Control Rac1-PAK1 Signaling and Actin Cytoskeleton for Dendritic Spine Maturation. *Cell*

reports, 31(10), 107744.

Lee SW, et al. (2019) EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis. *Developmental cell*, 50(3), 381.

Tajadura-Ortega V, et al. (2018) An RNAi screen of Rho signalling networks identifies RhoH as a regulator of Rac1 in prostate cancer cell migration. *BMC biology*, 16(1), 29.